BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15292314)

  • 1. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
    Brettenthaler N; De Geyter C; Huber PR; Keller U
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3835-40. PubMed ID: 15292314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
    Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
    Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
    Garmes HM; Tambascia MA; Zantut-Wittmann DE
    Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.
    Aroda VR; Ciaraldi TP; Burke P; Mudaliar S; Clopton P; Phillips S; Chang RJ; Henry RR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):469-76. PubMed ID: 18984667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
    Glintborg D; Hermann AP; Andersen M; Hagen C; Beck-Nielsen H; Veldhuis JD; Henriksen JE
    Fertil Steril; 2006 Aug; 86(2):385-97. PubMed ID: 16782094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).
    Valsamakis G; Lois K; Kumar S; Mastorakos G
    Hormones (Athens); 2013; 12(3):363-78. PubMed ID: 24121378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
    Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones for treatment of polycystic ovary syndrome.
    Stout DL; Fugate SE
    Pharmacotherapy; 2005 Feb; 25(2):244-52. PubMed ID: 15767238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
    Aigner E; Bachofner N; Klein K; De Geyter C; Hohla F; Patsch W; Datz C
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1229-35. PubMed ID: 19158194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
    Glintborg D; Støving RK; Hagen C; Hermann AP; Frystyk J; Veldhuis JD; Flyvbjerg A; Andersen M
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5605-12. PubMed ID: 16076946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.